Tenderwize
Zurück zur Suche

Open House Originale rebate agreement for Lamivudine/Abacavir/Dolutegravir

Techniker Krankenkasse·Hamburg, Germany·Deadline Feb 27, 2027 · 187 days left·Open·Supplies
Registrieren zum SpeichernOpen documents
Originaltitel der Bekanntmachung

Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-07 - Lamivudin/Abacavir/Dolutegravir (Wirkstoffkombination)

46/100

Opportunity Score

Needs reviewMedium complexity
SuppliesOpen
Warum diese Bewertung?

Chance

46 / 100

Komplexität

58 / 100

Risikofaktoren

Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...

Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...

Tiefe Portfolioanalyse

Tiefe Analyse der Unternehmenspassung

Verwendet:

  • Description
  • Industries & Services
  • Capabilities
  • Market & Experience
  • Certifications

Überblick

Moderate opportunity

Wichtige Fakten

  • Supplies contract
  • 1 lot
  • Duration until Feb 2027
  • Supply of pharmaceutical products for the medicinal combination Lamivudin/Abacavir/Dolutegravir.
  • Open House rebate agreements under § 130c(1) SGB V.
Vollständige Zusammenfassung anzeigen

This is an Open House supply arrangement by Techniker Krankenkasse for the pharmaceutical product combination Lamivudin/Abacavir/Dolutegravir (CPV 33600000). The notice states that all suitable pharmaceutical companies may join during the contract period, with no individual negotiations and no exclusivity. The contract runs from 01.03.2025 to 28.02.2027 at the latest, but no contract value is provided. Participation and contract documents are only available electronically via the buyer portal, while submission is not allowed through the portal and must be made by email with qualified electronic signature or by post. The notice also states that the publication is not considered a public procurement contract under procurement law, so remedies are directed to social courts rather than procurement review bodies.

Risiken

Submission through the portal is not allowed; the notice requires email with qualified electronic signature or postal s...

Only pharmaceutical companies meeting the AMG and authorisation conditions may participate; local representatives are e...

Analyse kann unvollständig sein

Nur ein Teil der Vergabeunterlagen wurde analysiert. Weitere Anforderungen, Zertifikate oder Einreichungsdokumente können in den übrigen Unterlagen enthalten sein.

Wichtige Anforderungen

Technical

  • Applicant must be a pharmaceutical company within the meaning of § 4(18) AMG for the offered medicinal products.
  • Applicant must have its seat in Germany, another EU Member State, or another EEA State.
  • Applicant must hold a valid marketing authorisation for the relevant medicinal product(s), or otherwise be entitled to place them on the market in its own name.

Auftraggeber

Ort

Hamburg, DEU

Kennung

992-80116-93

Tätigkeit

Health

Lose (1)

LOT-0001

Open House Originale rebate agreement for Lamivudine/Abacavir/Dolutegravir

Single lot covering Open House rebate agreements for the medicinal product combination Lamivudin/Abacavir/Dolutegravir. The scope is nationwide in Germany and the arrangement is open to all suitable pharmaceutical companies meeting the stated eligibility conditions. Source: structured data and XML notice.

SuppliesEU fundedElectronic submission

Ort

DE600, Germany

Dauer

Feb 2025 - Feb 2027

Kategorie

Pharmaceutical products

Frist

Deadline Feb 27, 2027

Vergabedetails

Veröffentlichungsdatum
20 Jan 2025
Sprachen
German

Referenzmetadaten

Rechtsgrundlage
32014L0024

Referenz-IDs

Ausschreibungs-ID
42947-2025

Dokumente (1)

Vergabedokument 1

Ähnliche Ausschreibungen

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)

Aug 31

Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР

Jul 9

Belgium – Pharmaceutical products – Antimycotica

Aug 27

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)

Aug 31

Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)

Sep 30

Denmark – Pharmaceutical products – Amgros 2027 1.1170.a

Sep 3